Chemical genetics-based development of small molecules targeting hepatitis C virus
- PMID: 28856597
- DOI: 10.1007/s12272-017-0949-3
Chemical genetics-based development of small molecules targeting hepatitis C virus
Abstract
Hepatitis C virus (HCV) infection is a major worldwide problem that has emerged as one of the most significant diseases affecting humans. There are currently no vaccines or efficient therapies without side effects, despite today's advanced medical technology. Currently, the common therapy for most patients (i.e. genotype 1) is combination of HCV-specific direct-acting antivirals (DAAs). Up to 2011, the standard of care (SOC) was a combination of peg-IFNα with ribavirin (RBV). After approval of NS3/4A protease inhibitor, SOC was peg-IFNα and RBV with either the first-generation DAAs boceprevir or telaprevir. In the past several years, various novel small molecules have been discovered and some of them (i.e., HCV polymerase, protease, helicase and entry inhibitors) have undergone clinical trials. Between 2013 and 2016, the second-generation DAA drugs simeprevir, asunaprevir, daclatasvir, dasabuvir, sofosbuvir, and elbasvir were approved, as well as the combinational drugs Harvoni®, Zepatier®, Technivie®, and Epclusa®. A number of reviews have been recently published describing the structure-activity relationship (SAR) in the development of HCV inhibitors and outlining current therapeutic approaches to hepatitis C infection. Target identification involves studying a drug's mechanism of action (MOA), and a variety of target identification methods have been developed in the past few years. Chemical biology has emerged as a powerful tool for studying biological processes using small molecules. The use of chemical genetic methods is a valuable strategy for studying the molecular mechanisms of the viral lifecycle and screening for anti-viral agents. Two general screening approaches have been employed: forward and reverse chemical genetics. This review reveals information on the small molecules in HCV drug discovery by using chemical genetics for targeting the HCV protein and describes successful examples of targets identified with these methods.
Keywords: Chemical genetics; Drug discovery; Hepatitis C virus.
Similar articles
-
Current race in the development of DAAs (direct-acting antivirals) against HCV.Biochem Pharmacol. 2014 Jun 15;89(4):441-52. doi: 10.1016/j.bcp.2014.04.005. Epub 2014 Apr 13. Biochem Pharmacol. 2014. PMID: 24735613
-
Emerging therapies for hepatitis C.Gut Liver. 2014 Sep;8(5):471-9. doi: 10.5009/gnl14083. Epub 2014 Aug 18. Gut Liver. 2014. PMID: 25228970 Free PMC article. Review.
-
Hepatitis C treatment: an incipient therapeutic revolution.Trends Mol Med. 2014 Jun;20(6):315-21. doi: 10.1016/j.molmed.2014.02.002. Epub 2014 Mar 11. Trends Mol Med. 2014. PMID: 24636306 Review.
-
Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy.Mini Rev Med Chem. 2018;18(7):584-596. doi: 10.2174/1389557517666170913111930. Mini Rev Med Chem. 2018. PMID: 28901852 Review.
-
Resistance mutations against HCV protease inhibitors and antiviral drug design.Curr Pharm Des. 2014;20(5):694-703. doi: 10.2174/13816128113199990008. Curr Pharm Des. 2014. PMID: 23688081 Review.
Cited by
-
The Human Replicative Helicase, the CMG Complex, as a Target for Anti-cancer Therapy.Front Mol Biosci. 2018 Mar 29;5:26. doi: 10.3389/fmolb.2018.00026. eCollection 2018. Front Mol Biosci. 2018. PMID: 29651420 Free PMC article. Review.
-
Repurposing of artesunate, an antimalarial drug, as a potential inhibitor of hepatitis E virus.Arch Virol. 2023 Apr 28;168(5):147. doi: 10.1007/s00705-023-05770-1. Arch Virol. 2023. PMID: 37115342 Free PMC article.
-
Evaluation of interactions between the hepatitis C virus NS3/4A and sulfonamidobenzamide based molecules using molecular docking, molecular dynamics simulations and binding free energy calculations.J Comput Aided Mol Des. 2023 Jan;37(1):53-65. doi: 10.1007/s10822-022-00490-1. Epub 2022 Nov 25. J Comput Aided Mol Des. 2023. PMID: 36427108 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous